Jan Tennvall

6.8k total citations · 1 hit paper
130 papers, 4.9k citations indexed

About

Jan Tennvall is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jan Tennvall has authored 130 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Radiology, Nuclear Medicine and Imaging, 43 papers in Oncology and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jan Tennvall's work include Radiopharmaceutical Chemistry and Applications (65 papers), Monoclonal and Polyclonal Antibodies Research (30 papers) and Thyroid Cancer Diagnosis and Treatment (24 papers). Jan Tennvall is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (65 papers), Monoclonal and Polyclonal Antibodies Research (30 papers) and Thyroid Cancer Diagnosis and Treatment (24 papers). Jan Tennvall collaborates with scholars based in Sweden, Netherlands and United States. Jan Tennvall's co-authors include Sven‐Erik Strand, Markus Luster, G. E. F. Lundell, Wim J.G. Oyen, Katarina Sjögreen Gleisner, Måns Åkerman, Tomas Ohlsson, Michael Ljungberg, Michael Garkavij and Michael Laßmann and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Jan Tennvall

130 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for radioiodine therapy of differentiated thyroid cancer

2008 474 citations Markus Luster, Sharon E. Clarke et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers

Countries citing papers authored by Jan Tennvall

Since Specialization

Citations

This map shows the geographic impact of Jan Tennvall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Tennvall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Tennvall more than expected).

Fields of papers citing papers by Jan Tennvall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Tennvall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Tennvall. The network helps show where Jan Tennvall may publish in the future.

Co-authorship network of co-authors of Jan Tennvall

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Tennvall. A scholar is included among the top collaborators of Jan Tennvall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Tennvall. Jan Tennvall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE 2024 ·Journal of Nuclear Medicine ·(unknown), Johan Gustafsson, Daniel Roth, Jan Tennvall, Johanna Svensson, Peter Bernhardt, Anna Åkesson, Elinore Wieslander, Anna Sundlöv, Katarina Sjögreen Gleisner	15
2	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) 2022 ·Journal of Clinical Oncology ·Alan L. Ho, Marek Dedecjus, Lori J. Wirth, R. Michael Tuttle, William B. Inabnet, Jan Tennvall, Fernanda Vaisman, Lars Bastholt, Andrew G. Gianoukakis, Patrice Rodien, Ralf Paschke, Rossella Elisei, David Viola, Karen So, Danielle Carroll, (unknown), (unknown), James A. Fagin, (unknown)	37
3	Sequential Radioimmunotherapy with ¹⁷⁷ Lu- and ²¹¹ At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model 2014 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), (unknown), Tom Bäck, Tomas Ohlsson, Holger Jensen, Rune Nilsson, Sture Lindegren, Jan Tennvall	7
4	Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with ¹⁷⁷ Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model 2012 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), Tomas Ohlsson, Rune Nilsson, Jan Tennvall	7
5	Repeated Radioimmunotherapy with ¹⁷⁷ Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model 2012 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), Tomas Ohlsson, Rune Nilsson, Jan Tennvall	10
6	Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial 2010 ·Annals of Oncology ·Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardière, Jan Tennvall, Ahmad Awada, Joaquín Marchena‐Gómez, (unknown), Muriel Licour, Martin Schlumberger	17
7	High‐dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model 2010 ·Cancer ·Linda Mårtensson, Rune Nilsson, Tomas Ohlsson, Hans‐Olov Sjögren, Sven‐Erik Strand, Jan Tennvall	13
8	Guidelines for radioiodine therapy of differentiated thyroid cancer breakdown → 2008 ·European Journal of Nuclear Medicine and Molecular Imaging ·Markus Luster, Sharon E. Clarke, Markus Dietlein, Michael Laßmann, Peter Lind, Wim J.G. Oyen, Jan Tennvall, Emilio Bombardieri	474
9	Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy 2005 ·Acta Oncologica ·Cécilia Hindorf, Ola Lindén, Jan Tennvall, Karin Wingårdh, Sven‐Erik Strand	14
10	Biotinylation, Pharmacokinetics, and Extracorporeal Adsorption of Humanized MAb ¹¹¹ In-MN14 Using an Avidin-Affinity Column in Rats 2003 ·Cancer Biotherapy and Radiopharmaceuticals ·Zhong-Min Wang, Michael Garkavij, Tomas Ohlsson, Sven‐Erik Strand, (unknown), Jan Tennvall	4
11	Tumour therapy with radionuclides: assessment of progress and problems 2003 ·Radiotherapy and Oncology ·Jörgen Carlsson, Eva Forssell‐Aronsson, S.-O. Hietala, Torgny Stigbrand, Jan Tennvall	88
12	FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma 2002 ·Head & Neck ·Eva Brun, Elisabeth Kjellén, Jan Tennvall, Tomas Ohlsson, A. Sandell, Roland Perfekt, Johan Wennerberg, Sven‐Erik Strand	210
13	Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin 2002 ·Cancer ·Zhongmin Wang, Michael Garkavij, Jan Tennvall, Tomas Ohlsson, Sven‐Erik Strand, (unknown)	6
14	A Swedish Study of Chemoradiation in Squamous Cell Carcinoma of the Esophagus 2001 ·Acta Oncologica ·Dag Stockeld, Jan Tennvall, Gunnar Wagenius, Maria Albertsson, Lars Bäckman, Ola Brodin, Magdalena Cwikiel, L Granström, G Gustafsson, Sven Gustavsson, Göran Hambraeus, Rolf Lewensohn, Svante Sjöstedt, Hans Strander, Bengt Åberg, Jan Fagerberg	18
15	Improving tumor‐to‐normal‐tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin‐biotin concept 1997 ·Cancer ·Jan Tennvall, Michael Garkavij, Jianqing Chen, Hans Sjögren, Sven‐Erik Strand	1
16	ENHANCED RADIOIMMUNOTARGETING OF 125I-L6-BIOTIN MAb BY COMBINING PRELOAD OF COLD L6 MAB AND SUBSEQUENT IMMUNOADSORPTION ( ECIA ) 1994 ·Journal of Immunotherapy ·Jan Tennvall, Michael Garkavij, (unknown), Kristina Norrgren, Rune Nilsson, (unknown), Hans Sjögren	2
17	A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio 1994 ·Cancer ·Sven‐Erik Strand, Kristina Norrgren, Michael Garkavij, (unknown), Rune Nilsson, Hans Sjögren, Jan Tennvall	7
18	Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption 1994 ·Medical & Biological Engineering & Computing ·Sven‐Erik Strand, Michael Ljungberg, Jan Tennvall, Kristina Norrgren, Michael Garkavij	9
19	Kinetics of ²⁰¹ T1 Uptake in Adenomas and Well-Differentiated Carcinomas of the Thyroid a Double Isotope Investigation with ⁹⁹ Tc ^m and ²⁰¹ T1 1984 ·Acta Radiologica Oncology ·Jan Tennvall, J. Palmer, A. Biörklund, T. Möller, Jonas Ranstam, Måns Åkerman	8
20	Preoperative Scintigraphy With Correlation to Cytology and Histopathology in Carcinoma of the Thyroid 1983 ·Acta Radiologica Oncology ·Jan Tennvall, E. Cederquist, T. Möller, (unknown), Måns Åkerman	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact